Fast Market Research

Now Available: Investigation Report on China Sildenafil Market, 2009-2018

Fast Market Research recommends "Investigation Report on China Sildenafil Market, 2009-2018" from CRI, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 04/09/2014 -- Description
There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine self-image generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.

Sildenafil, developed by Pfizer Co., Ltd., was originally developed as a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) to treat cardiovascular diseases. However, the medicine did not avail against the disease. In April 1991, the clinical research of sildenafil officially failed, but a side effect in the report attracted the researchers' attention. They found that patients were unwilling to return the remaining medication after the trial. Through further investigation researchers discovered that the medication can improve the patients' sexual life. Under the permission of Pfizer's top management, experiment about sildenafil's effect on penile corpus cavernosum smooth muscle was carried out. The medication (sildenafil produced by Pfizer with the trade name "Viagra") was approved to the market by FDA on March 27, 1998, which soon became a world-famous product of Pfizer Co., Ltd.

View Full Report Details and Table of Contents

Besides erectile dysfunction, sildenafil is also useful for the prevention and treatment of high-altitude pulmonary edema and altitude sickness.

The global sales revenue of Viagra reached USD 2.05 billion in 2012. Indications patent owned by Pfizer expires in 2014. Viagra entered China in 1998. According to CRI's investigation on sample hospitals in China, the sales revenue of Viagra keeps rising steadily without sharp increase. CRI reckons that most of its sales revenue in China is from drug stores instead of hospitals since Viagra can be easily bought in many drug stores without prescription though it is a prescription drug in China. For Viagra is an important medication in treatment of sexual dysfunction in China, many domestic enterprises started to produce its generic drug. A sildenafil generic drug produced by certain Chinese pharmaceutical enterprise is expected to appear on the market in the third quarter of 2014. Sildenafil produced by other enterprises will be launched soon in succession. Price of Viagra in China may be reduced as the generic drugs enter the market. However, the price reduction will not prevent Pfizer's market share from decreasing since prices of homemade generic drugs will be even lower.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Investigation Report on China Duloxetine Market, 2009-2018
- Investigation Report on China Insulin Aspart Market, 2009-2018
- Investigation Report on China Pregabalin Market, 2009-2018
- Investigation Report on China Insulin Lispro Market, 2009-2018
- Investigation Report on China Budesonide Market, 2009-2018
- Investigation Report on China Imatinib Market, 2009-2018
- Investigation Report on China Esomeprazole Market, 2009-2018
- Investigation Report on China Adalimumab Market, 2010-2018
- Investigation Report on China Esomeprazole Market, 2009-2018
- Investigation Report on China Aripiprazole Market, 2009-2018